These products are often referred to as compounded GLP-1 medications. SAHPRAs enforcement action On 23 May 2026, SAHPRA announced that it had intensified enforcement action against the unlawful manufacturing and distribution of unregistered GLP-1 and GIP medicines containing semaglutide, tirzepatide, or combination formulations
The aim of this review is to synthesise current evidence, highlight guideline evolution, and outline practical strategies for risk assessment and management
These included gastrointestinal lesions, pancreatic injury, hepatic damage, cardiac tissue impairment, endothelial disruption, and alterations in vascular pressure regulation
Liraglutide is a long-acting peptide analog of GLP-1, because of a better resistance to DDP-IV-mediated degradation due to the presence of a fatty acid side-chain
Ferroptosis was the main tubular cell death that can significantly amplify inflammation
Parece tener efectos comparables a los antidepresivos estndar y causa menos efectos secundarios